Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine

Journal of Clinical Oncology

Volumn 16, Issue 5, 1998, Pages 1795-1802

  Budman, Daniel R ^a   Meropol, Neal J ^a   Reigner, Bruno ^a   Creaven, Patrick J ^a   Lichtman, Stuart M ^a   Berghorn, Elmer ^a   Behr, Joanne ^a   Gordon, R J ^a   Osterwalder, Bruno ^a   Griffin, Thomas ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL;

ABDOMINAL PAIN; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; FEMALE; HUMAN; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT OUTCOME; VERTIGO; VOMITING;

EID: 0031859855     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.5.1795     Document Type: Article

References (17)

1. Heidelberger C, Chaudhari NK, Danneberg P, et al: Fluorinated pyrimidines. A new class of tumor-inhibitory compounds. Nature 179:663-666, 1957
2. Christophidis N, Vajda FJE, Lucas I, et al: Fluorouracil therapy in patients with carcinoma of the large bowel: A pharmacokinetic comparison of various rates and routes of administration. Clin Pharmacokinet 3:330-336, 1978
3. Meropol NJ, Creaven PJ, Petrelli NJ: Metastatic colorectal cancer: Advances in biochemical modulation and new drug development. Semin Oncol 22:509-524, 1995
4. Budman DR, Lichtman SM: Investigational drugs, in Perry MC (ed): The Chemotherapy Sourcebook (ed 2). Baltimore, MD, Williams & Wilkins, 1996, pp 479-558
5. Ishikawa T, Sawada N, Sekiguchi F, et al: Xeloda (capecitabine), a new oral fluoropyrimidine carbamate with an improved efficacy profile over other fluoropyrimidines. Proc Am Soc Clin Oncol 16:796a, 1997 (abstr)
6. Cao S, Lu K, Ishitsuka H, et al: Antitumor efficacy of capecitabine against fluorouracil-sensitive and -resistant tumors. Proc Am Soc Clin Oncol 16:795a, 1997 (abstr)
7. Ishikawa T, Utoh M, Sawada N, et al: Xeloda (capecitabine): An orally available tumor-selective fluoropyrimidine cabamate. Proc Am Soc Clin Oncol 16:727a, 1997 (abstr)
8. Hoffman-LaRoche I: Investigational Drug Brochure RO-09-1978. On file with the US Food and Drug Administration (third version)
9. Brundage MD, Peter JL, Zee B: Assessing the reliability of two toxicity scales: Implications for interpreting data. J Natl Cancer Inst 85:1138-1148, 1993
10. Gibaldi M, Perrier D: Pharmacokinetics (ed 2). New York, NY. Marcel Decker, 1982, pp 409-417
11. Liu G, Franssen E, Fitch MI, et al: Patient preference for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110-115, 1997
12. van Triest B, van Groeningen CJ, Pinedo HM: Current chemotherapeutic possibilities in the treatment of colorectal cancer. Eur J Cancer 37A: 1193-1197, 1995
13. Sumizawa T, Furukawa T, Haraguchi M, et al: Thymidine phosphorylase activity associated with platelet derived endothelial cell growth factor. J Biochem 114:9-14, 1993
14. Fox SB, Westwood M, Moghaddam A, et al: The angiogenic factor platelet-derived endothelial growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. Br J Cancer 73:275-280, 1996
15. Relf M, LeJeune S, Scott PAE, et al: Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor B-I. platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotropin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57:963-969, 1997
16. Griffiths L, Dachs GU, Bicknell R, et al: The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo. Cancer Res 57:570-572, 1997
17. Muller M, Mader RM, Steiner B, et al: 5-Fluorouracil kinetics in the interstitial tumor space: Clinical response in breast cancer patients. Cancer Res 57:2598-2601, 1997